At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 147 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
LY545694 49 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of the Effects of LY545694, an iGluR5 Antagonist, in the Treatment of Subjects With Osteoarthritis Knee Pain
In Brief
A Phase 2 clinical trial evaluating Placebo, LY545694 49 mg, and 1 other intervention for Osteoarthritis Knee Pain. Completed, enrolled 147 participants across 10 sites in 3 countries.
Detailed Summary
To gather data on whether a new drug for osteoarthritis knee pain will be safe and have an effect on pain levels.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis Knee Pain
CountriesPuerto Rico, Romania, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2008
First PostedNov 2008
Primary CompletionJan 2010
TodayJul 2026
First PostedNov 14, 2008
Enrollment StartNov 1, 2008
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 17.6 years ago
Interventions
Placebodrug
LY545694 placebo BID po for 5 weeks
LY545694 49 mgdrug
LY545694 49 mg BID po for 5 weeks.
LY545694 105 mgdrug
LY545694 105 mg BID po for 5 weeks.